Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

1877 - Adherence to cisplatin-based regimens prescription in "fit" patients fulfilling platinum eligibility criteria. Impact on outcomes: a retrospective international study of invasive/advanced cancer of the urothelium (RISC) analysis


09 Oct 2016


Poster display


Aristotelis Bamias


Annals of Oncology (2016) 27 (6): 266-295. 10.1093/annonc/mdw373


A. Bamias1, K. Tzannis1, M. Liontos2, S.J. Crabb3, L. Harshman4, U. De Giorgi5, J. Bellmunt6, Y. Wong7, S.K. Pal8, S. Ladoire9, C.N. Sternberg10, T.B. Powles11, E.Y. Yu12, G. Niegisch13, A. Necchi14, U. Vaishampayan15, N. Agarwal16, J. Rosenberg17, R. Investigators18

Author affiliations

  • 1 Clinical Therapeutics, University of Athens, 115 28 - Athens/GR
  • 2 Oncology Unit, Department Of Clinical Therapeutics, Alexandra Hospital, 115 28 - Athens/GR
  • 3 Medical Oncology, University of Southampton, Southampton/GB
  • 4 Medical Oncology, Dana-Farber Cancer Institute, Boston/US
  • 5 Medical Oncology, Istituto Tumori della Romagna I.R.S.T., Meldola/IT
  • 6 Oncology, Dana-Farber Cancer Institute, Boston, MA/US
  • 7 Medical Oncology, Fox Chase Cancer Center, Philadelphia/US
  • 8 Medical Oncology And Experimental Therapuetics, City of Hope, 91010 - Duarte/US
  • 9 Medical Oncology, Centre Georges-François Leclerc (Dijon), Dijon/FR
  • 10 Medical Oncology, Azienda Ospedaliera S. Camillo Forlanini, Roma/IT
  • 11 Department Of Medical Oncology, St. Bartholomew's Hospital, EC1A 7BE - London/GB
  • 12 Medical Oncology, Univ. Washington/VAPSHCS, Seattle/US
  • 13 Medical Oncology, Univesitätsklinikum Düsseldorf, Düsseldorf/DE
  • 14 Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 15 Medical Oncology, Karmanos Cancer Institute, Detroit/US
  • 16 Medical Oncology, Huntsman Cancer Institute, Salt Lake City/US
  • 17 Medical Oncology, Memorial Sloan Kettering Cancer Center, New York/US
  • 18 Oncology, Mount SInai Medical College, New York/US


Abstract 1877


Cisplatin-based chemotherapy is the treatment of choice in metastatic urothelial cancer (mUC). Nevertheless, about 50% of patients do not receive this treatment. Recently, specific criteria for unfitness-for-cisplatin (UFC) have been published. We used a multinational database to study the impact of adherence to UFC criteria in the outcome of unselected mUC patients


Selection criteria: diagnosis of mUC, transitional, mixed, squamous and adeno histologies, survival data available. Major end point: Overall survival (OS). UFC was defined according to Galsky et al (2011).


From 1828 mUC patients 441 (24%) did not receive any chemotherapy. These patients had a significantly shorter median OS (Table). 1361 patients (median fup: 31 months) were included in the analysis of the following treatment types: cisplatin-based (689;50%), carboplatin-based (404;30%), no cis- or carbo-platin [other (268;20%)]. Cisplatin therapy was associated with longer OS (Table). 971 patients had full data regarding UFC. The following deviations from the UFC criteria were noted: 21% and 32% of the carboplatin and the other groups were fit-for-cisplatin, while 38% of the cisplatin-treated patients fulfilled at least one UFC criterion. UFC patients had inferior outcome. This effect was significant only in cisplatin-treated patients (Table), while the benefit from cisplatin was also more pronounced within the fit-for-cisplatin patients. This cisplatin therapy-UFC interaction was significant (p = 0.0343)

Median OS (months) 95% CI p
1st-line chemotherapy Yes (n = 1499) No (n = 475) 14.6 5.1 13.4-15.5 4.2-6.2


A sizable proportion of fit-for-cisplatin patients do not receive cisplatin-based chemotherapy. Use of cisplatin for those patients may have potential to improve outcomes. On the contrary, unfit-for-cisplatin patients have a worse outcome and more efficient therapies should be sought.

Clinical trial identification

Legal entity responsible for the study



Icahn School of Medicine at Mount Sinai, USA


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.